New member of NexPlasmaGen's Business Advisory Committee | NexPlasmaGen
17321
post-template-default,single,single-post,postid-17321,single-format-standard,bridge-core-2.6.4,qode-page-transition-enabled,ajax_fade,page_not_loaded,,qode-theme-ver-24.9,qode-theme-bridge,disabled_footer_top,qode_header_in_grid,qode-wpml-enabled,wpb-js-composer js-comp-ver-7.7,vc_responsive

New member of NexPlasmaGen’s Business Advisory Committee

20 Feb New member of NexPlasmaGen’s Business Advisory Committee

Posted at 12:41h in Uncategorized by
0 Likes

February 20, 2026, New member of NexPlasmaGen’s Business Advisory Committee

Montreal / February 20, 2026 – NexPlasmaGen is immensely proud to announce that Mr. Howard Hechler has joined NexPlasmaGen’s Business Advisory Committee!

 

Howard Hechler has a 20-year track record of transforming innovative life sciences companies through strategic leadership, capital raising, product commercialization, and deal closing. His expertise spans medical technology, biopharmaceuticals, diagnostics, and AI/digital health, with proven success as CEO, COO, and corporate development leader, driving turnarounds and growing companies from startups to FDA approval and subsequent commercial launch. Most recently, Howard served as CEO of Lumicell (breast cancer diagnostics), and previously in various roles at Locust Walk, PolarityTE, Smith & Nephew, Medtronic, and Mallinckrodt Pharmaceuticals. Howard graduated cum laude with a Bachelor of Arts degree from Harvard University and received his MBA and Juris Doctor degrees from the University of Virginia.

NexPlasmaGen is truly privileged to be advised by Howard because of his experience and skills extremely relevant to NexPlasmaGen’s mission and stage of development.

 

ABOUT NEXPLASMAGEN

NexPlasmaGen converges the emerging field of cold plasma technology into personalized cancer treatment. We develop high-precision cold plasma systems with the potential to kill cancer cells while sparing the healthy tissue surrounding the treated area. The first application of NexPlasmaGen is in the treatment of breast cancer. Its patented cold plasma medical device is used to improve the results of breast-conserving therapy for the benefit of patients.

 

Contact

Valérie Léveillé, CEO/Founder

Tel. : 1-514-229-9458

Email : valerie.leveille@nexplasmagen.com

Website : https://nexplasmagen.com/

No Comments

Post A Comment